000889138 001__ 889138
000889138 005__ 20221117180421.0
000889138 0247_ $$2doi$$a10.1007/s00259-020-04817-8
000889138 0247_ $$2ISSN$$a0340-6997
000889138 0247_ $$2ISSN$$a1432-105X
000889138 0247_ $$2ISSN$$a1619-7070
000889138 0247_ $$2ISSN$$a1619-7089
000889138 0247_ $$2Handle$$a2128/32239
000889138 0247_ $$2pmid$$a32388612
000889138 0247_ $$2WOS$$aWOS:000531214000004
000889138 037__ $$aFZJ-2021-00063
000889138 041__ $$aEnglish
000889138 082__ $$a610
000889138 1001_ $$0P:(DE-HGF)0$$aMorbelli, Silvia$$b0$$eCorresponding author
000889138 245__ $$aEANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0
000889138 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2020
000889138 3367_ $$2DRIVER$$aarticle
000889138 3367_ $$2DataCite$$aOutput Types/Journal article
000889138 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1667369608_15986
000889138 3367_ $$2BibTeX$$aARTICLE
000889138 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000889138 3367_ $$00$$2EndNote$$aJournal Article
000889138 520__ $$aPurposeThis joint practice guideline or procedure standard was developed collaboratively by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The goal of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of dopaminergic imaging in parkinsonian syndromes.MethodsCurrently nuclear medicine investigations can assess both presynaptic and postsynaptic function of dopaminergic synapses. To date both EANM and SNMMI have published procedural guidelines for dopamine transporter imaging with single photon emission computed tomography (SPECT) (in 2009 and 2011, respectively). An EANM guideline for D2 SPECT imaging is also available (2009). Since the publication of these previous guidelines, new lines of evidence have been made available on semiquantification, harmonization, comparison with normal datasets, and longitudinal analyses of dopamine transporter imaging with SPECT. Similarly, details on acquisition protocols and simplified quantification methods are now available for dopamine transporter imaging with PET, including recently developed fluorinated tracers. Finally, [18F]fluorodopa PET is now used in some centers for the differential diagnosis of parkinsonism, although procedural guidelines aiming to define standard procedures for [18F]fluorodopa imaging in this setting are still lacking.ConclusionAll these emerging issues are addressed in the present procedural guidelines for dopaminergic imaging in parkinsonian syndromes.
000889138 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000889138 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x1
000889138 588__ $$aDataset connected to CrossRef
000889138 7001_ $$0P:(DE-HGF)0$$aEsposito, Giuseppe$$b1
000889138 7001_ $$0P:(DE-HGF)0$$aArbizu, Javier$$b2
000889138 7001_ $$0P:(DE-HGF)0$$aBarthel, Henryk$$b3
000889138 7001_ $$0P:(DE-HGF)0$$aBoellaard, Ronald$$b4
000889138 7001_ $$0P:(DE-HGF)0$$aBohnen, Nico I.$$b5
000889138 7001_ $$0P:(DE-HGF)0$$aBrooks, David J$$b6
000889138 7001_ $$0P:(DE-HGF)0$$aDarcourt, Jacques$$b7
000889138 7001_ $$0P:(DE-HGF)0$$aDickson, John C.$$b8
000889138 7001_ $$0P:(DE-HGF)0$$aDouglas, David$$b9
000889138 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b10
000889138 7001_ $$0P:(DE-HGF)0$$aDubroff, Jacob$$b11
000889138 7001_ $$0P:(DE-HGF)0$$aEkmekcioglu, Ozgul$$b12
000889138 7001_ $$0P:(DE-HGF)0$$aGaribotto, Valentina$$b13
000889138 7001_ $$0P:(DE-HGF)0$$aHerscovitch, Peter$$b14
000889138 7001_ $$0P:(DE-HGF)0$$aKuo, Phillip$$b15
000889138 7001_ $$0P:(DE-HGF)0$$aLammertsma, Adriaan$$b16
000889138 7001_ $$0P:(DE-HGF)0$$aPappata, Sabina$$b17
000889138 7001_ $$0P:(DE-HGF)0$$aPeñuelas, Iván$$b18
000889138 7001_ $$0P:(DE-HGF)0$$aSeibyl, John$$b19
000889138 7001_ $$0P:(DE-HGF)0$$aSemah, Franck$$b20
000889138 7001_ $$0P:(DE-HGF)0$$aTossici-Bolt, Livia$$b21
000889138 7001_ $$0P:(DE-HGF)0$$aVan de Giessen, Elsmarieke$$b22
000889138 7001_ $$0P:(DE-HGF)0$$aVan Laere, Koen$$b23
000889138 7001_ $$0P:(DE-HGF)0$$aVarrone, Andrea$$b24
000889138 7001_ $$0P:(DE-HGF)0$$aWanner, Michele$$b25
000889138 7001_ $$0P:(DE-HGF)0$$aZubal, George$$b26
000889138 7001_ $$0P:(DE-HGF)0$$aLaw, Ian$$b27
000889138 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-020-04817-8$$gVol. 47, no. 8, p. 1885 - 1912$$n8$$p1885 - 1912$$tEuropean journal of nuclear medicine and molecular imaging$$v47$$x1619-7089$$y2020
000889138 8564_ $$uhttps://juser.fz-juelich.de/record/889138/files/Morbelli2020_Article_EANMPracticeGuidelineSNMMIProc.pdf$$yRestricted$$zStatID:(DE-HGF)0599
000889138 8564_ $$uhttps://juser.fz-juelich.de/record/889138/files/Morbelli2020_Article_EANMPracticeGuidelineSNMMIProc_PostPrint.docx$$yOpenAccess$$zStatID:(DE-HGF)0510
000889138 909CO $$ooai:juser.fz-juelich.de:889138$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000889138 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b10$$kFZJ
000889138 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000889138 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x1
000889138 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-29
000889138 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-29
000889138 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-29
000889138 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000889138 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-08-29
000889138 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2018$$d2020-08-29
000889138 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-08-29
000889138 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2020-08-29$$wger
000889138 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-29
000889138 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000889138 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-08-29
000889138 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2018$$d2020-08-29
000889138 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-29
000889138 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-08-29
000889138 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-29
000889138 920__ $$lyes
000889138 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000889138 980__ $$ajournal
000889138 980__ $$aVDB
000889138 980__ $$aUNRESTRICTED
000889138 980__ $$aI:(DE-Juel1)INM-2-20090406
000889138 9801_ $$aFullTexts